Updated:
Codman Neuro
Codman Neuro is a Raynham-based neurotechnology firm specializing in neurosurgical and neurovascular devices, with roots in the 1838 Codman & Shurtleff...
Codman Neuro
Codman Neuro traces its lineage to Codman & Shurtleff, a medical device company founded in 1838 that became part of Johnson & Johnson's DePuy Synthes franchise. The entity now operates as a focused neurotechnology business based in Raynham, Massachusetts, specializing in surgical instruments and implants for neurosurgery and neurovascular procedures. The firm's core strategy involves developing and distributing devices for cranial and spinal surgery, including programmable shunt systems, microsurgical instruments, and cranial stabilization equipment. Its product portfolio is used in hospitals and surgical centers globally, with a sales footprint reaching North America, Europe, and select Asia-Pacific markets. Codman Neuro's devices compete alongside those from Medtronic, Stryker, and B. Braun in the neurosurgical device category. With no publicly disclosed AUM or standalone management team, Codman Neuro functions as an operating division within a larger corporate structure rather than an independent investment vehicle. No team size or recent capital deployment events are verifiable through public records. The structural differentiator is the firm's deep niche focus: Codman Neuro operates exclusively in neurosurgical and neurovascular device categories, leveraging decades of regulatory expertise and clinical relationships built since the Codman brand's 19th-century origins.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Raynham
Corporate office
Raynham, MA, United States
Sector focus
Frequently asked questions
What is Codman Neuro's primary business focus?
Codman Neuro develops and distributes medical devices for neurosurgery and neurovascular procedures, including shunt systems, microsurgical instruments, and cranial stabilization equipment. Its products serve hospitals and surgical centers worldwide (per public record).
Is Codman Neuro a standalone company or part of a larger organization?
Codman Neuro operates as a division within the DePuy Synthes franchise of Johnson & Johnson. It is not an independent investment vehicle but a product-focused business unit with its own operational strategy and sales infrastructure (per public record).
What is the history of the Codman brand?
The Codman brand was established by Codman & Shurtleff, a medical device company founded in 1838. It was acquired by Johnson & Johnson and integrated into the DePuy Synthes neurosurgery portfolio, maintaining the Codman Neuro name for neurospecific products (per public record).
Who competes with Codman Neuro in the neurosurgical device market?
Codman Neuro's primary competitors include Medtronic's neurosurgery division, Stryker's neurotechnology unit, and B. Braun's Aesculap brand. These firms also offer programmable shunt systems, cranial fixation devices, and microsurgical instruments (per public record).
Where are Codman Neuro's products used?
Codman Neuro devices are used in hospitals and surgical centers across North America, Europe, and parts of Asia-Pacific. The firm's sales and distribution network supports neurosurgeons and interventional neuroradiologists in clinical settings (per public record).
Does Codman Neuro function as an investor or asset manager?
No. Codman Neuro is a medical device operating division, not an investment firm. No AUM, fund structures, or capital deployment programs are associated with the entity (per public record).
What is Codman Neuro's regulatory history?
Codman Neuro products hold FDA approvals and CE markings for various neurosurgical devices. The firm's regulatory compliance is managed within Johnson & Johnson's broader quality systems framework (per public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: